Table 1 Oncogenicity and actionable potential of EGFR mutations targeted by CDx tests.

From: Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions

Characteristic

Both (N = 110)

ODxTT only (N = 6)

Not targeted (N = 100)

Oncogenicity, n (%)

 Oncogenic

104 (95%)

3 (50%)

3 (3%)

 Likely oncogenic

5 (5%)

2 (33%)

3 (3%)

 Resistance

1 (1%)

1 (17%)

0 (0%)

 Inconclusive

0 (0%)

0 (0%)

1 (1%)

 Likely neutral

0 (0%)

0 (0%)

1 (1%)

 Unknown

0 (0%)

0 (0%)

92 (92%)

CIViC or OncoKB, n (%)

 Therapeutic

110 (100%)

2 (33%)

4 (4%)

 Unknown

0

4 (67%)

96 (96%)

  1. Both, targeted by both ODxTT and AmoyDx panel; ODxTT, Oncomine Dx Target Test; CIViC, Clinical Interpretation of Variants in Cancer; OncoKB, a precision oncology knowledge base.
Back to article page